Immunovia AB (publ) (0G8X.L)
| Previous close | 37.13 |
| Open | 34.49 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 34.49 - 34.49 |
| 52-week range | 34.49 - 34.49 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 3.697B |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.80 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
SThree: Total Voting Rights
SThree (STEM) SThree: Total Voting Rights 03-May-2022 / 09:34 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. 3 May 2022 SThree plc Total Voting Rights In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, SThree plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital as at 30 April 2022 consisted of 133,
- Business Wire
Immunovia, Inc. Receives Final Approval to Begin Patient Testing with the IMMray® PanCan-d Test
MARLBOROUGH, Mass., August 04, 2021--Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer. This approval was received from the Massachusetts Department of Public Health on August 3, 2021. Immunovia, Inc. received its CLIA Certificate of Registration on June 21, 2021 (C
